Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field
Human 3 with Brom and Sam22 Heinä 2025

Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field

Ryan Field is the CEO of Kernel, a brain-computer interface company founded by Bryan Johnson. Kernel is a cutting edge, non-invasive BCI that uses fNIRS to image the brain. Imagine if getting an MRI was as easy as putting on a bike helmet: that's Kernel in a nutshell.

Kernel is developing several applications on top of their device including (A) predicting which antidepressant you will respond best to and (B) BrainAge, a cognitive assesment that tells you how young your brain is relative to your chronological age.

Ryan joins Brom Rector and Sam Tabone on the podcast to discuss:

(0:00) - Ryan’s background

(7:30) - history of Kernel

(10:00) - non-invasive VS invasive BCI (Kernel vs NeuraLink)

(25:00) - what Kernel can do: depression treatment response + brain age

(31:00) - Kernel's AI: black box or hand tuned features

(45:00) - How Kernel can detect cognitive impairment

(55:30) - Kernel's alcohol study

(58:00) - Kernel vs cheap neurotechand more!Get your Brain Age measured at https://www.kernel.com/brainage

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(33)

Dave Messina - YC founder turned investor talks TechBio

Dave Messina - YC founder turned investor talks TechBio

Ever wondered what Pioneer Fund’s Future of Health Fund is excited about? Want to know how to impress Dave Messina? Are you curious about how different funds communicate and interact?Give a listen to ...

6 Heinä 1h 16min

$HIMS Q2 Results - our take as healthcare venture capitalists

$HIMS Q2 Results - our take as healthcare venture capitalists

Brom Rector and Sam Tabone from XEIA Venture Partners - a VC firm that invests in the future of human health, wellbeing and performance - discuss $HIMS Q2 results and the HIMS business more broadly. W...

5 Elo 20251h 24min

Investing in Psychedelic BioTech [August 2025 webinar replay]

Investing in Psychedelic BioTech [August 2025 webinar replay]

Watch the video recording on YouTube: https://youtu.be/BM6x59oMnKg?si=qF0xDvgUMvU60ctP2025 has been the start of a bull period for psychedelic medicine.​Psychedelic Biotechs like GH Research, Compass ...

30 Heinä 202558min

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

The past few years have been rough for psychedelic and shroom stocks, but recent news from ATAI (and Recognify), Compass Pathways and GH Research + positive regulatory tailwinds from RFK and MAHA make...

29 Heinä 202516min

How to start a VC fund

How to start a VC fund

I interviewed Michael Huseby to learn about his life story and his new book: Fundamentals: Your Friendly Guide to Investment Funds and SyndicationsThis is a great listen for anyone interested in start...

15 Heinä 20251h 20min

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Replay of our webinar on investing in brain computer interfaces. Join our upcoming July 30th event on investing in psychedelic biotech: psybio.org

12 Heinä 20251h 9min

Designing Novel Brain Drugs with Xylo Bio

Designing Novel Brain Drugs with Xylo Bio

Xylo is a biotech startup that is using computational methods to design novel brain drugs to treat mental health disorders and neurodegeneration. Many of their drug candidates are inspired by naturall...

8 Heinä 20251h